Also called: FOXO4 Compound, FOXO4-DRI UK, FOXO4 peptide
FOXO4-DRI is a lab-made peptide, which is a tiny chain of building blocks called amino acids. It was designed by scientists to study aging. It belongs to a group of compounds sometimes called longevity peptides. Researchers, not doctors, are the main people working with it.
In lab studies with old mice, this peptide seemed to help clear out worn-out cells that build up as animals age. Those tired cells can make tissues work poorly. The peptide works by interfering with a handshake between two proteins inside cells, which may push old damaged cells to remove themselves. In the mouse studies, researchers saw better fitness and some signs of healthier fur and kidneys.
Very little is known about how it acts in people. There are no finished human studies, so its safety and effects in humans are unknown. It is not an approved medicine anywhere. Anyone reading about it should know the evidence comes from animal work only, and handling it carries real risks. (Word on scope: the crawled pages only discuss FOXO4-DRI briefly — as a listing in longevity research guides and as a vendor product — so many practical details remain undocumented here.)
Benefits
The benefits people report — backed by research.
You just read the research on FOXO4-DRI. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Evidence
Every claim above traces back to a source you can check — here are 7 of them.
PubChem - Compound - Foxo4-dri
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
PubChem - Compound - FOXO4-DRI acetate
News
Dated, sourced reporting that mentions FOXO4-DRI.
Wondering how FOXO4-DRI pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Explore by goal
Related peptides
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.